logo

Intersect Ent Inc (XENT)



Trade XENT now with
  Date
  Headline
11/5/2018 7:12:47 AM Intersect ENT Q3 Loss/shr Widens To $0.25 From $0.15 Last Year
8/1/2018 8:21:44 AM Intersect ENT Q2 Net Loss Per Share $0.14 Vs Loss $0.08 Last Year
7/17/2018 4:06:48 PM Minerva Neurosciences Elects Jeryl Hilleman To Board Of Directors
5/21/2018 8:09:44 AM SetPoint Medical Appoints Ankit Shah To Lead Commercialization And Marketing
1/8/2018 8:19:43 AM Intersect ENT 2017 Revenue Up 22% Year Over Year
1/7/2018 9:50:22 AM New Drugs Approved In December
11/3/2017 9:19:17 AM Wedbush Is Lowering Intersect ENT Inc (XENT) 2017 Estimate To -0.66 From -0.63
11/3/2017 9:18:54 AM Wedbush Is Raising Intersect ENT Inc (XENT) 2018 Rev. Estimate To 112.7 M From 111.6 M
11/3/2017 9:18:40 AM Wedbush Is Increasing Intersect ENT Inc (XENT) 2017 Rev. Estimate To 94.6 M From 93.5 M
8/2/2017 12:41:31 PM Wedbush Is Lowering Intersect ENT Inc (XENT) 2018 Rev. Estimate To 111.6 M From 112.0 M
8/2/2017 12:41:10 PM Wedbush Is Raising Intersect ENT Inc (XENT) 2017 Rev. Estimate To 93.5 M From 91.1 M
8/2/2017 12:40:36 PM Wedbush Is Increasing Intersect ENT Inc (XENT) Q4 17 Rev. Estimate To 27.8 M From 27.7 M
8/2/2017 12:40:13 PM Wedbush Is Increasing Intersect ENT Inc (XENT) Q3 17 Rev. Estimate To 21.3 M From 20.4 M
8/2/2017 12:39:47 PM Wedbush Is Increasing Intersect ENT Inc (XENT) 2017 Estimate To -0.63 From -0.72
8/2/2017 12:39:24 PM Wedbush Is Cutting Intersect ENT Inc (XENT) Q3 17 Estimate To -0.26 From -0.24
5/3/2017 8:42:59 AM Wedbush Is Cutting Intersect ENT Inc (XENT) 2018 Estimate To -0.37 From -0.36
5/3/2017 8:42:47 AM Wedbush Is Raising Intersect ENT Inc (XENT) 2017 Estimate To -0.72 From -0.74
5/3/2017 8:42:24 AM Wedbush Is Raising Intersect ENT Inc (XENT) 2018 Rev. Estimate To 112.0 M From 108.8 M